# Jeremy Richardson

Episod podcast teratas
Dikemas kini:

5. Khanike oder Krismes

This episode, entirely in Yiddish, focuses on the pressures on interwar immigrant and second generation Jews to engage with English life and the particular dilemma of what to do about Christmas. We hear Katie Brown’s story of a family negotiating Hanukkah and Christmas and the street song ‘Mayn ...

6. Look back in shmaltz

Episode 6 takes a wallow in nostalgia. Nadia and Vivi listen to a shmaltzy song yearning for Jewish Whitechapel and look at how postwar Yiddish and English-language writers remembered and reinvented the East End. We hear a story, movingly read by Miriam Margolyes, in which the smell of tradition ...

Market shifts and AI: reshaping global equities

Jeremy Richardson, Senior Portfolio Manager, Global Equities, RBC Global Asset Management Limited, discusses the rapid changes in market dynamics, including shifts in regional and industry performance. Jeremy also reflects on the ongoing evolution of AI as a significant investment theme and the ...

Human Nature: Roots

For the final episode of our Human Nature series, we, appropriately, go back to our roots. Part 1: After a dangerous incident, Kalā Holiday begins to question his work as a tour guide in his ancestral land of Hawai’i. Part 2: Jeremy Richardson must reconcile his roots in coal country with his id ...

The Forgiving Father

The Forgiving Father – AM by Jeremy Richardson on Luke 5:11-32

Navigating global equities in a world of change

Jeremy Richardson, Senior Portfolio Manager of Global Equities at RBC Global Asset Management Limited, explores critical themes shaping global equities. He discusses AI’s transformative market impact, currency fluctuations and regional market returns, healthcare innovations like GLP-1 weight-lo ...

The Parable of the Sower [all age]

The Parable of the Sower [all age] – AM by Jeremy Richardson on Luke 8:1-15

Pharmaceutical Executive Daily: UCB to Acquire Candid Therapeutics

In today's Pharmaceutical Executive Daily, UCB announces a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion, a new commentary by Jeremy Richardson argues that MFN pricing and shifting policy expectations are making affordable direct-to-patient programs at scale an opera ...

Why direct-to-patient is the future of pharma access (Sponsored)

Direct-to-patient models are no longer an experiment - they're becoming a critical part of the modern prescription journey. In this sponsored episode of The Top Line, host Kelly Hogan talks with Jeremy Richardson, chief commercial officer at GiftHealth, about how DTP is redefining access, transp ...

Episode 2 | Jeremy Richardson

Welcome to episode 2 of The Session Podcast. In this episode, Jeremy Richardson of Olliepop Studios joins me for a follow up conversation to expand on responses from his feature in The Session Print Issue 3. Jeremy talks on how his filming started, his current sessions filming at Megaranch and o ...